| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| Other Sizes |
| ln Vitro |
DDAO exhibited a fluorescence quantum yield (ΦF) of 0.39 in ethanol, using rhodamine B (ΦF = 0.89 in ethanol) as a standard reference. [2]
The product from the reaction of the probe AB1 with hydrogen peroxide was isolated and confirmed as DDAO by ¹H NMR and HPLC analysis; the HPLC retention time of DDAO was 8.13 min. [2] |
|---|---|
| ln Vivo |
DDAO generated from the reaction of AB1 with H₂O₂ can be imaged in deep tissue. A premixed solution of AB1 with H₂O₂ injected intramuscularly into mouse leg produced a peak emission intensity of 7.1 × 10⁸ p⁻¹ cm⁻² sr⁻¹ at 660 nm, whereas no fluorescence was detectable in the leg treated with AB1 alone. [1]
In a mouse model of LPS-induced acute inflammation, intraperitoneal injection of LPS followed by AB1 led to strong fluorescence (λex/λem = 605/660 nm) attributed to DDAO production, with LPS-treated mice exhibiting 3-fold higher fluorescence intensity than PBS-treated controls. [1] |
| Cell Assay |
HeLa cells were incubated with AB1 (5 μM) for 2 h at 37 °C, then treated with H₂O₂ (100 μM) or PMA (1 μg/mL) for 30 min. The formation of DDAO was monitored by confocal microscopy using red channel (640-740 nm) with excitation at 535 nm or 600 nm. In cells treated with H₂O₂ or PMA, a strong red fluorescence (emission at 660 nm) was observed due to DDAO generation, while cells loaded with AB1 alone showed weak red fluorescence. The ratiometric fluorescence change (Fred/Fyellow) increased from 0.53 (probe alone) to 1.94 (PMA stimulation). [1]
|
| References |
|
| Additional Infomation |
1,3-Dichloro-7-hydroxy-9,9-dimethyl-9H-acridin-2-one is a cyclic ketone belonging to the acridine class of compounds. It can be used as a fluorescent dye.
DDAO was synthesized according to a reported procedure. Its fluorescence emission is at 656 nm, and it shows a redshifted emission at 660 nm when formed from the probe AB1 upon H₂O₂-mediated cleavage. The bathochromic shift results from a strong intramolecular charge transfer (ICT) process. DDAO has been applied as a far-red fluorogenic substrate for various enzymes, but no reactive oxygen species (ROS) probe based on DDAO had been reported prior to this study. [2] |
| Molecular Formula |
C15H11NO2CL2
|
|---|---|
| Molecular Weight |
308.15934
|
| Exact Mass |
307.016
|
| CAS # |
118290-05-4
|
| PubChem CID |
2762655
|
| Appearance |
Purple to purplish red solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
449.0±45.0 °C at 760 mmHg
|
| Flash Point |
225.4±28.7 °C
|
| Vapour Pressure |
0.0±1.1 mmHg at 25°C
|
| Index of Refraction |
1.666
|
| LogP |
3.31
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
20
|
| Complexity |
550
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1(C2=CC(=O)C=CC2=NC3=CC(=C(C(=C31)Cl)O)Cl)C
|
| InChi Key |
BRDJPCFGLMKJRU-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H11Cl2NO2/c1-15(2)8-5-7(19)3-4-10(8)18-11-6-9(16)14(20)13(17)12(11)15/h3-6,20H,1-2H3
|
| Chemical Name |
6,8-dichloro-7-hydroxy-9,9-dimethylacridin-2-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~10.42 mg/mL (~33.81 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 1.04 mg/mL (3.37 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 10.4 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 1.04 mg/mL (3.37 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 10.4 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2451 mL | 16.2253 mL | 32.4507 mL | |
| 5 mM | 0.6490 mL | 3.2451 mL | 6.4901 mL | |
| 10 mM | 0.3245 mL | 1.6225 mL | 3.2451 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT05943210 | Recruiting | Radiation: Short Course Radiation Therapy (scRT) Procedure: Total Mesenteric Excision (TME) |
Rectal Cancer | Weill Medical College of Cornell University | 2023-05-22 | Not Applicable |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
